The facility, called the
Wesana will initially fund the buildout of the BrainStorm center with a 1.5 MM cash contribution and will execute clinical drug development work in addition to developing proprietary intellectual property in parallel, with the proper FDA and IRB approvals, to develop compounds of interest that will enhance neural performance and act as neuro-protectants for the high-risk populations supported by the center of excellence. This work is forecast to begin in Q4 ’21.
“The University of
BrainStorm’s team of experts will work with leading athletes, Olympians and military personnel to design and implement means of protecting the brain prophylactically pre-game or pre-battle as well as in acute post-injury scenarios. This will be a key benefit for athletes participating in high-impact sports, as well as military and government personnel. Development will begin within the next 30 days. Upon completion of construction, the facility will be operational and evaluating athletes, veterans and patients within nine months.
“The BrainStorm Lab was founded on the principle that an ounce of prevention is worth a pound of cure. Historically, brain health has fixated on measuring or mitigating degradation after an injury takes place. BrainStorm is a collaboration of some of the nation’s most forward-thinking scientists focused on building armor around the brain before the injury occurs,” added
“Through the
About Wesana
Wesana is an emerging life sciences company championing the development and delivery of psychedelic and naturally-sourced therapies to treat traumatic brain injury (TBI). Through extensive clinical research and academic partnerships, Wesana is developing evidence-based formulations and protocols that empower patients to overcome neurological, psychological and mental health ailments caused by trauma.
Learn more at www.wesanahealth.com
About the
The
Forward-Looking Information and Statements
This news release contains "forward-looking information" within the meaning of applicable securities laws relating to future partnerships, collaborative research and the focus of the Company’s business. Any such forward-looking statements may be identified by words such as "expects", "anticipates", "intends", "contemplates", "believes", "projects", "plans" and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance regarding the participation in, or success of, partnerships or collaborative research or that the Company will continue its business as described above. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Readers are encouraged to refer to the Listing Statement filed on Company's profile on SEDAR at www.sedar.com for information as to the risks and other factors which may affect the Company’s business objectives and strategic plans.
For more information, please contact: Investor Contact:Allison Soss KCSA Strategic Communications Email: WesanaIR@kcsa.com Phone: 212-896-1267 Media Contact:Nick Opich /Annie Graf KCSA Strategic Communications Email: Wesana@kcsa.com Phone: 212-896-1206 / 786-390-2644 On behalf of the Board of Directors:Daniel Carcillo , Chief Executive Officer Phone: (773) 236-7972
Source:
2021 GlobeNewswire, Inc., source